Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lucid Diagnostics Inc. (LUCD : NSDQ)

• Company Description    Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $2.21 Daily Weekly Monthly 20 Day Moving Average: 177,671 shares Shares Outstanding: 37.93 (millions) Market Capitalization: $83.83 (millions) Beta: 52 Week High: $13.52 52 Week Low: $1.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.07% 5.78% 12 Week -38.44% -35.19% Year To Date -58.85% -52.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE GRAND CENTRAL PLACE SUITE 4600 - NEW YORK,NY 10165 USA ph: 212-949-4319 fax: - pavmed@lavoiehealthscience.com http://www.luciddx.com

• General Corporate Information    Officers Lishan Aklog - Chief Executive Officer & Chairman Stanley N. Lapidus - Vice Chairman Dennis M. McGrath - President & Chief Financial Officer Aster Angagaw - Director James L. Cox - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 54948X109 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 37.93 Most Recent Split Date: (:1) Beta: Market Capitalization: $83.83 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.42 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.80 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 3.71 12/31/21 - 13.45 09/30/21 - 0.09 Quick Ratio 03/31/22 - - 12/31/21 - 13.45 09/30/21 - 0.09 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -5,615.60 09/30/21 - - Book Value 03/31/22 - 1.23 12/31/21 - 1.49 09/30/21 - -0.65 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©